Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
Study Details
Study Description
Brief Summary
The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to a 10% hypersensitivity response was considered acceptable.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Vitrase A single intradermal dose of 4.5 USP units of Vitrase at one site and the same volume of saline at a distant site for comparative control. |
Drug: Vitrase
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Hypersensitivity [1-2 days]
Incidence of hypersensitivity to Vitrase following a single intradermal injection of 4.5 USP units Vitrase.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Agreed to avoid disallowed meds
Exclusion Criteria:
-
Known hypersensitivity to hyaluronidase and/or bee sting
-
Previous known exposure to ovine hyaluronidase or bovine hyaluronidase
-
Atopic individuals assessed by medical history
-
Topical/inhaled/systemic corticosteroids within 30 days
-
Concurrent use of antihistamines or anti-inflammatory during study
-
Active or chronic disease likely to affect immune function
-
History of alcohol/drug abuse within 6 months
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Solano Clinical Research (A Division of Dow Pharmaceutical Sciences) | Davis | California | United States | 95616 |
Sponsors and Collaborators
- Bausch & Lomb Incorporated
Investigators
- Study Director: Lisa R Grillone, PhD, ISTA Pharmaceuticals, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ISTA-VIT-CS05